Cargando…

Assessment of Drug Sensitivity of Human Leukaemic Myeloblasts: I. Labelling Human Myeloblasts with (125)IUdR for Survival Studies in Mice

The compound (125)IUdR can be incorporated in a stable form into the DNA of cells. The isotope is released if labelled cells or their progeny die. Consequently the rate of (125)I excretion from mice can be used to follow the fate of labelled cells in vivo. Using these principles we show: (1) Suffici...

Descripción completa

Detalles Bibliográficos
Autores principales: FalcãO, R. P., Sonis, S., MacLennan, I. C. M., Chassoux, D., Davies, A. J. S., Munro, T. R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1977
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025418/
https://www.ncbi.nlm.nih.gov/pubmed/270372
_version_ 1782136759135502336
author FalcãO, R. P.
Sonis, S.
MacLennan, I. C. M.
Chassoux, D.
Davies, A. J. S.
Munro, T. R.
author_facet FalcãO, R. P.
Sonis, S.
MacLennan, I. C. M.
Chassoux, D.
Davies, A. J. S.
Munro, T. R.
author_sort FalcãO, R. P.
collection PubMed
description The compound (125)IUdR can be incorporated in a stable form into the DNA of cells. The isotope is released if labelled cells or their progeny die. Consequently the rate of (125)I excretion from mice can be used to follow the fate of labelled cells in vivo. Using these principles we show: (1) Sufficient label can be incorporated in vitro into both fresh and cryopreserved human leukaemic myeloblasts, in non-toxic concentrations, to allow their survival in mice to be estimated by whole-body counting; (2) The release of isotope from labelled cells is sufficiently slow to offer reasonable expectation that this technique can be used for assessing the sensitivity of myeloblasts to cytotoxic agents in vivo (an application described in the second paper in this series, Sonis, Falcão and MacLennon, 1977); (3) The rate of (125)Iexcretion from mice injected with myeloblasts from different donors varies. This probably reflects different rates of spontaneous death of injected myeloblasts; (4) Active rejection of myeloblasts starts within 48 h of their injection into mice; (5) Indirect evidence that phagocytic cells may be active agents in myeloblast destruction in mice; (6) Various methods of immunologically depriving mice were assessed to see if they would result in a useful increase in survival of injected human myeloblasts. We conclude that there is little advantage and some limitations in using mice thus deprived; (7) One of the agents used for immunological deprivation—silica powder—markedly decreased the rate of (125)I loss from mice injected with labelled killed myeloblasts. This experience emphasizes the importance of including the killed-cell control in this assay.
format Text
id pubmed-2025418
institution National Center for Biotechnology Information
language English
publishDate 1977
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20254182009-09-10 Assessment of Drug Sensitivity of Human Leukaemic Myeloblasts: I. Labelling Human Myeloblasts with (125)IUdR for Survival Studies in Mice FalcãO, R. P. Sonis, S. MacLennan, I. C. M. Chassoux, D. Davies, A. J. S. Munro, T. R. Br J Cancer Articles The compound (125)IUdR can be incorporated in a stable form into the DNA of cells. The isotope is released if labelled cells or their progeny die. Consequently the rate of (125)I excretion from mice can be used to follow the fate of labelled cells in vivo. Using these principles we show: (1) Sufficient label can be incorporated in vitro into both fresh and cryopreserved human leukaemic myeloblasts, in non-toxic concentrations, to allow their survival in mice to be estimated by whole-body counting; (2) The release of isotope from labelled cells is sufficiently slow to offer reasonable expectation that this technique can be used for assessing the sensitivity of myeloblasts to cytotoxic agents in vivo (an application described in the second paper in this series, Sonis, Falcão and MacLennon, 1977); (3) The rate of (125)Iexcretion from mice injected with myeloblasts from different donors varies. This probably reflects different rates of spontaneous death of injected myeloblasts; (4) Active rejection of myeloblasts starts within 48 h of their injection into mice; (5) Indirect evidence that phagocytic cells may be active agents in myeloblast destruction in mice; (6) Various methods of immunologically depriving mice were assessed to see if they would result in a useful increase in survival of injected human myeloblasts. We conclude that there is little advantage and some limitations in using mice thus deprived; (7) One of the agents used for immunological deprivation—silica powder—markedly decreased the rate of (125)I loss from mice injected with labelled killed myeloblasts. This experience emphasizes the importance of including the killed-cell control in this assay. Nature Publishing Group 1977-09 /pmc/articles/PMC2025418/ /pubmed/270372 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Articles
FalcãO, R. P.
Sonis, S.
MacLennan, I. C. M.
Chassoux, D.
Davies, A. J. S.
Munro, T. R.
Assessment of Drug Sensitivity of Human Leukaemic Myeloblasts: I. Labelling Human Myeloblasts with (125)IUdR for Survival Studies in Mice
title Assessment of Drug Sensitivity of Human Leukaemic Myeloblasts: I. Labelling Human Myeloblasts with (125)IUdR for Survival Studies in Mice
title_full Assessment of Drug Sensitivity of Human Leukaemic Myeloblasts: I. Labelling Human Myeloblasts with (125)IUdR for Survival Studies in Mice
title_fullStr Assessment of Drug Sensitivity of Human Leukaemic Myeloblasts: I. Labelling Human Myeloblasts with (125)IUdR for Survival Studies in Mice
title_full_unstemmed Assessment of Drug Sensitivity of Human Leukaemic Myeloblasts: I. Labelling Human Myeloblasts with (125)IUdR for Survival Studies in Mice
title_short Assessment of Drug Sensitivity of Human Leukaemic Myeloblasts: I. Labelling Human Myeloblasts with (125)IUdR for Survival Studies in Mice
title_sort assessment of drug sensitivity of human leukaemic myeloblasts: i. labelling human myeloblasts with (125)iudr for survival studies in mice
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025418/
https://www.ncbi.nlm.nih.gov/pubmed/270372
work_keys_str_mv AT falcaorp assessmentofdrugsensitivityofhumanleukaemicmyeloblastsilabellinghumanmyeloblastswith125iudrforsurvivalstudiesinmice
AT soniss assessmentofdrugsensitivityofhumanleukaemicmyeloblastsilabellinghumanmyeloblastswith125iudrforsurvivalstudiesinmice
AT maclennanicm assessmentofdrugsensitivityofhumanleukaemicmyeloblastsilabellinghumanmyeloblastswith125iudrforsurvivalstudiesinmice
AT chassouxd assessmentofdrugsensitivityofhumanleukaemicmyeloblastsilabellinghumanmyeloblastswith125iudrforsurvivalstudiesinmice
AT daviesajs assessmentofdrugsensitivityofhumanleukaemicmyeloblastsilabellinghumanmyeloblastswith125iudrforsurvivalstudiesinmice
AT munrotr assessmentofdrugsensitivityofhumanleukaemicmyeloblastsilabellinghumanmyeloblastswith125iudrforsurvivalstudiesinmice